Company news

Aim Immunotech Inc. (AMEX:AIM) news

Aim Immunotech Inc. news releases on 6ix. Latest, Sep 3, 2026: AIM ImmunoTech Significantly Expands Ampligen Global Patent Estate with Long COVID Protection…

Aim Immunotech Inc. (AMEX:AIM) news

Press releases & updates

AIM ImmunoTech Significantly Expands Ampligen Global Patent Estate with Long COVID Protection across Europe and the United Kingdom Through 2041

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen(R) Toward Planned Phase 3 Development in Pancreatic Cancer

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer

AIM ImmunoTech : Ahead of Schedule on 'Last Dose' DURIPANC Critical Clinical Inflection Point

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities

AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP

AIM ImmunoTech Provides Routine Update on Annual Filings

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKS

AIMIA REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

AIM ImmunoTech Announces Closing of its Rights Offering

AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

AIM ImmunoTech Announces Commencement of Rights Offering

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

AIM ImmunoTech Announces Stock Dividend

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering